NASDAQ: NRSN
Neurosense Therapeutics Ltd Stock Ownership - Who owns Neurosense Therapeutics?

Insider buying vs selling

Have Neurosense Therapeutics Ltd insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Alon BennoonChief Executive Officer2026-06-16250,000$0.80
$200.00kBuy
Or EisenbergChief Financial Officer2026-06-16250,000$0.80
$200.00kBuy

1 of 1

NRSN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NRSN insiders and whales buy or sell their stock.

NRSN Shareholders

What type of owners hold Neurosense Therapeutics Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Alon Bennoon13.93%4,534,233$2.15MInsider
Or Eisenberg4.62%1,504,050$712.92kInsider
Hagit Binder1.60%521,806$247.34kInsider
Ferenc Tracik1.31%428,011$202.88kInsider
Mark Leuchtenberger0.38%122,951$58.28kInsider
Christine A. Pellizzari0.31%99,898$47.35kInsider
Cary J. Claiborne0.31%99,898$47.35kInsider
Yorkville Advisors Global LP0.24%78,000$36.97kInstitution
Revital Mandillevin0.24%76,844$36.42kInsider
Roy Golan0.24%76,844$36.42kInsider

1 of 3

NRSN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NRSN1.17%22.96%Net BuyingNet Buying
RKTO4.11%42.24%Net Selling
COCP0.86%99.14%Net BuyingNet Buying
AIXC0.54%93.56%
PLRZ2.23%5.29%Net Selling

Neurosense Therapeutics Stock Ownership FAQ

Who owns Neurosense Therapeutics?

Neurosense Therapeutics (NASDAQ: NRSN) is owned by 1.17% institutional shareholders, 22.96% Neurosense Therapeutics insiders, and 75.88% retail investors. Alon Bennoon is the largest individual Neurosense Therapeutics shareholder, owning 4.53M shares representing 13.93% of the company. Alon Bennoon's Neurosense Therapeutics shares are currently valued at $2.13M.

If you're new to stock investing, here's how to buy Neurosense Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.